Genvec (GNVC) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'GNVC	'
Entity Common Stock, Shares Outstanding	'	13,678,285
Entity Registrant Name	'GENVEC INC	'
Entity Central Index Key	'0000934473	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$4,970	$4,150
Investments	2,131	11,105
Accounts receivable, net	264	947
Prepaid expenses and other	211	226
Total current assets	7,576	16,428
Property and equipment, net	800	805
Other assets	281	197
Total assets	8,657	17,430
Current liabilities:	'	'
Accounts payable	1,076	1,500
Accrued expenses and other	2,048	2,187
Total current liabilities	3,124	3,687
Commitments (Note 7)	0	0
Stockholders’ equity:	'	'
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued and outstanding in 2013 and 2012	0	0
Common stock, $0.001 par value; 30,000 shares authorized; 13,678 and 12,948 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	14	13
Additional paid-in capital	280,426	279,518
Accumulated other comprehensive loss	-14	-27
Accumulated deficit	-274,893	-265,761
Total stockholders' equity	5,533	13,743
Total liabilities and stockholders’ equity	$8,657	$17,430

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000	5,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	30,000	30,000
Common stock, shares issued	13,678	12,948
Common stock, shares outstanding	13,678	12,948

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues from strategic alliances and research contracts	$1,582	$2,128	$3,537	$7,832
Operating expenses:	'	'	'	'
Research and development	1,619	3,380	5,350	11,284
General and administrative	2,926	2,799	7,335	7,475
Total operating expenses	4,545	6,179	12,685	18,759
Operating loss	-2,963	-4,051	-9,148	-10,927
Other income:	'	'	'	'
Interest and Other Income, net	2	12	16	31
Net loss	-2,961	-4,039	-9,132	-10,896
Basic and diluted net loss per share	($0.23)	($0.31)	($0.71)	($0.84)
Shares used in computation of basic and diluted net loss per share	12,948	12,938	12,948	12,938
Comprehensive Loss:	'	'	'	'
Net loss	-2,961	-4,039	-9,132	-10,896
Unrealized holding gain/(loss) on securities available for sale	-6	18	13	-1
Comprehensive loss	($2,967)	($4,021)	($9,119)	($10,897)

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($9,132)	($10,896)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	139	181
Non-cash charges for stock-based compensation	909	950
Impairment of long lived assets	229	0
Changes in current assets and liabilities, net	135	1,846
Changes in non-current assets, net	-84	-64
Net cash used in operating activities	-7,804	-7,983
Cash flows from investing activities:	'	'
Purchases of property and equipment	-363	-266
Purchases of investment securities	-2,313	-25,928
Proceeds from sale and maturities of investment securities	11,300	35,035
Net cash provided by investing activities	8,624	8,841
Cash flows from financing activities:	0	0
Increase in cash and cash equivalents	820	858
Beginning balance of cash and cash equivalents	4,150	4,114
Ending balance of cash and cash equivalents	$4,970	$4,972

General

General	9 Months Ended
	Sep. 30, 2013
General Disclosure [Abstract]	'
General	'
	-1	General
	Basis of Presentation
	The condensed financial statements included herein have been prepared by GenVec, Inc. (GenVec, we, our, or the Company) without audit pursuant to the rules and regulations of the Securities and Exchange Commission (SEC).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. We believe the disclosures are adequate to make the information presented not misleading.  The condensed financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2012 Annual Report on Form 10-K filed with the SEC.
	In the opinion of management, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of September 30, 2013 and December 31, 2012, the results of its operations for the three-month and nine-month periods ended September 30, 2013 and September 30, 2012, and cash flows for the nine-month periods ended September 30, 2013 and September 30, 2012.  The results of operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
	Business
	GenVec is a biopharmaceutical company working with leading companies and organizations such as Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and the U.S. Government to leverage GenVec’s proprietary gene-delivery technologies to address the prevention and treatment of significant health concerns. GenVec’s lead program, in the field of regenerative medicine and licensed to Novartis, is for the development of novel treatments for hearing loss and balance disorders.  We anticipate that Novartis will initiate a phase 1 clinical trial in 2014.
	Key components of our strategy moving forward include:
		⋅	Working with Novartis to facilitate the development of first-in-class products for the treatment of hearing and balance disorders;
		⋅	Developing a sustainable revenue base by licensing rights to our proprietary vector and cell line technologies to additional companies and organizations;
		⋅	Licensing our pre-clinical vaccine candidates for the prevention of RSV and the treatment of HSV-2 infection; and
		⋅	Minimizing our cash burn by operating our business in a cost-efficient manner.
	Our core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body.
	Our research and development activities have been focused on identifying product candidates that utilize our technology platform and represent potential commercial opportunities. For example, preclinical research in hearing loss and balance disorders has indicated that the delivery of the atonal gene using GenVec’s adenovector technology may have the potential to restore hearing and balance function. We are working with Novartis on the discovery and development of novel treatments for hearing loss and balance disorders. There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem.
	Recent Events
	Our current operating strategy was adopted on September 4, 2013, when we announced that our Board of Directors withdrew a Plan of Complete Liquidation and Dissolution of the Company (the Plan of Dissolution) that had been adopted by the Board of Directors on May 24, 2013, subject to stockholder approval. After announcing the approval of the Plan of Dissolution by the Board of Directors, the Company received several proposals for transactions with the Company, including transactions to purchase all or portions of the Company's assets or to engage in mergers with private companies that were looking to use the Company principally as a means to become publicly traded. As part of the Board of Directors' efforts to seek to maximize the value for stockholders and to provide stockholders with appropriate information for their consideration, the Board of Directors considered these proposals. Given that it was considering these proposals, the Board of Directors also authorized Cannacord Genuity Inc., an investment banking firm, to solicit additional proposals for the acquisition of our assets, and on June 24, 2013, the Company announced publicly that it had received and was considering proposals. The Board of Directors viewed the ability of the counterparties to complete the proposed transactions, in a timely manner, if at all, as extremely risky, the prospects for preserving value as very uncertain and the likelihood of receiving significant consideration in an asset sale as unlikely. The process that the Company went through in evaluating alternative proposals, the business developments during that time, the challenges in monetizing the Company's assets in the near term for values the Board of Directors thought would be fair, and the time that the process took, led the Board of Directors to conclude on September 4, 2013 that it was in the best interests of the Company's stockholders to withdraw the Plan of Dissolution and pursue the Company's current operating strategy.
	In going through the process of considering the Plan of Dissolution and alternative transactions, we worked to terminate or further curtail a number of our contractual obligations and a significant portion of our operations. We also ceased to support some programs at the levels at which they were previously supported, or at all. On July 29, 2013, for example, we entered into a modification with the U.S. Naval Medical Logistics Command to terminate contractual obligations under our agreement related to dengue fever and malaria vaccine development efforts at the U.S. Naval Medical Research Center. In furtherance of these efforts, we announced on June 28, 2013, that we had terminated the employment of 30 of our then remaining 41 employees, and as of the date of this Quarterly Report on Form 10-Q we have 9 employees.
	Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the success of our collaboration with Novartis and our success in entering into other licensing or collaboration transactions. Based on our current business operations, we estimate we have sufficient resources to fund our operations through at least the end of 2014.
	Use of Estimates
	The preparation of financial statements, in conformity with U.S. generally accepted accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities on the date of the financial statements, and revenues and expenses during the period. Critical accounting estimates involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate was made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period and would have a material impact on the presentation of our financial condition, results of operations, or cash flows. Our most critical accounting estimates relate to accounting policies for strategic alliance and research contract revenues, clinical trial expenses and research and development activities, and stock-based arrangements. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates.
	Revenue Recognition
	Revenue is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and determinable, (iii) delivery of the services or products has occurred, and (iv) collectability of the contract amounts is considered probable.
	Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments.  Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period.  If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.  Non-refundable research and development fees for which no future performance obligations exist are recognized when collection is assured.  Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement.  Determination of whether a milestone meets the aforementioned conditions involves the judgment of management.
	Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract.  Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change.  Reimbursable costs under such contracts are subject to audit and retroactive adjustment.  Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received.  Contract revenues are adjusted to actual upon final audit and retroactive adjustment.  Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels.  Payments received in advance of work performed are recorded as deferred revenue.
	Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract.  Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received.  During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables.  Recoverable contract costs that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect costs.  Payments received in advance of customer acceptance are recorded as deferred revenue.  Once customer acceptance has been received, revenue and recoverable contract costs are recognized.  Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period.  Any known or probable losses on projects are charged to operations in the period in which such losses are determined.
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (Topic 220). The standard requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. The Company’s adoption of the provisions of this guidance on January 1, 2013 did not have a material impact on our financial position, results of operations, or cash flows.
	There were no other new pronouncements effective as of September 30, 2013 that had a material effect on our financial position, results of operations, or cash flows.  Additionally, other new pronouncements issued but not effective until after September 30, 2013 are not expected to have a material effect on our financial position, results of operations, or cash flows.
	Reclassifications
	Certain reclassifications have been made to prior period amounts to conform to our current period presentation.  Such reclassifications have no effect on net loss as previously reported.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	-2	Fair Value Measurements
	For assets and liabilities measured at fair value we utilize FASB Accounting Standards Codification (ASC) Section 820 “Fair Value Measurements and Disclosures” (ASC 820) which defines fair value and establishes a framework for fair value measurements. This standard establishes a three-level hierarchy for disclosure of fair value measurements. The hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels of inputs used to measure fair value are as follows:
	·	Level 1 – Quoted prices in active markets for identical assets or liabilities;
	·	Level 2 – Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and other inputs that are observable (e.g., interest rates, yield curves, volatilities and default rates, among others)  or that can be corroborated by observable market data; and
	·	Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.
	The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet as of September 30, 2013:
					Quoted Prices in
					Active Markets for		Significant
			Total Carrying		Identical		Other Observable
			Value on the		Assets/Liabilities		Inputs
	(In thousands)		Balance Sheet		(Level 1)		(Level 2)
	Assets:
	Cash and cash equivalents		$	4,970	$	4,970	$	-
	Corporate notes and bonds			654		-		654
	U.S. Government and agency securities			1,419		-		1,419
	Equity security			58		58		-
	Total assets at fair value		$	7,101	$	5,028	$	2,073
	The following table presents information about assets and liabilities recorded at fair value on a recurring basis as of December 31, 2012 on the Condensed Balance Sheet:
					Quoted Prices in
					Active Markets for		Significant
			Total Carrying		Identical		Other Observable
			Value on the		Assets/Liabilities		Inputs
	(In thousands)		Balance Sheet		(Level 1)		(Level 2)
	Assets:
	Cash and cash equivalents		$	4,150	$	4,150	$	-
	Corporate notes and bonds			6,871		-		6,871
	U.S. Government and agency securities			4,189		-		4,189
	Equity security			45		45		-
	Total assets at fair value		$	15,255	$	4,195	$	11,060
	We determine fair value for marketable securities with Level 1 inputs through quoted market prices and have classified them as available-for-sale.  Our Level 2 marketable securities consist of corporate and U.S. agency bonds with maturities of less than 12 months.
	We review all investments for other-than-temporary impairment at least quarterly or as indicators of impairment exist.  Indicators of impairment include the duration and severity of the decline in fair value as well as the intent and ability to hold the investment to allow for a recovery in the market value of the investment.  In addition, we consider qualitative factors that include: (i) the financial condition and business plans of the investee, including its future earnings potential; (ii) the investee’s credit rating; and (iii) the current and expected market and industry conditions in which the investee operates.  If a decline in the fair value of an investment is deemed by management to be other-than-temporary, we write down the cost basis of the investment to fair value, and the amount of the write-down is included in net earnings.  Such a determination is dependent on the facts and circumstances relating to each investment.  We have determined there have been no such impairments in 2013 or 2012.
	All unrealized holding gains or losses related to our investments in marketable securities are reflected in accumulated other comprehensive loss in stockholders’ equity. The change in accumulated other comprehensive loss was a net unrealized gain of $13,000 and a net unrealized loss of $1,000 for the nine months ended September 30, 2013 and September 30, 2012, respectively.

StockBased_Compensation_Expens

Stock-Based Compensation Expense	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation Expense	'
	-3	Stock-Based Compensation Expense
	The following table summarizes stock-based compensation expense related to employee stock options for the three-month and nine-month periods ended September 30, 2013 and September 30, 2012, which was allocated as follows:
			Three Months Ended						Nine Months Ended
			September 30,						September 30,
			2013			2012			2013		2012
			(in thousands)						(in thousands)
	Research and development		$	83		$	208		$	503	$	636
	General and administrative			200			104			406		314
			$	283		$	312		$	909	$	950
	We use the Black-Scholes pricing model to value stock options.  The estimated fair value of employee stock options granted during the nine months ended September 30, 2013 and 2012 was calculated using the Black-Scholes model with the following weighted-average assumptions:
			For the Nine				For the Nine
			Months Ended				Months Ended
			September 30, 2013				September 30, 2012
	Risk-free interest rate			1.05	%			1.04	%
	Expected dividend yield			0	%			0	%
	Expected volatility			98.09	%			97.97	%
	Expected life (years)			6.2				6.34
	Weighted-average fair value of options granted		$	1.22			$	2
	The risk-free interest rate assumptions are based upon various U.S. Treasury rates as of the date of the grants, 1.00% to 2.63%, for the nine months ended September 30, 2013 and 0.81% to 1.58% for the nine months ended September 30, 2012.
	The expected dividend yield is based on the assumption that we do not expect to declare a dividend over the life of the options.
	The expected volatility assumptions for 2013 and 2012 are based on the weighted average volatility for the most recent one-year period as well as the volatility over the expected life of 6.20 years and 6.34 years, respectively.
	The expected life of employee stock options represents the weighted average combining the actual life of options that have already been exercised or cancelled with the expected life of all outstanding options.  The expected life of outstanding options is calculated assuming the options will be exercised in part at the midpoint of the vesting date (four years) and in part at the full contractual term (ten years).
	The Company estimates forfeiture rates at the time of grant and revises these estimates, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  Forfeitures are estimated based on the demographics of current option holders and standard probabilities of employee turnover.  We do not record tax-related effects on stock-based compensation given our historical and anticipated operating experience and offsetting changes in our valuation allowance, which fully reserves against potential deferred tax assets.
	Stock Options
	The following table summarizes the stock option activity for the nine months ended September 30, 2013:
						Weighted			Weighted
						average			average		Aggregate
			Number			exercise			contractual		intrinsic
	(in thousands,		of shares			price			life (years)		value
	except exercise price and contractual term data)
	Stock options outstanding, December 31, 2012			1,409		$	7.06
	Granted			646			1.57
	Forfeited			-549			2.29
	Expired			-183			13.27
	Stock options outstanding at September 30, 2013			1,323		$	5.5			7.72	$	9
	Vested or expected to vest at September 30, 2013			1,258		$	5.68			7.65	$	9
	Exercisable at September 30, 2013			908		$	6.97			7.19	$	-
	Unrecognized stock-based compensation related to stock options was approximately $0.7 million as of September 30, 2013. This amount is expected to be expensed over a weighted average period of 2.35 years.  There were no options exercised during the nine months ended September 30, 2013 or 2012.
	The following table summarizes information about our stock options outstanding as of September 30, 2013:
			Outstanding								Exercisable
						Weighted
						average			Weighted				Weighted
						remaining			average				average
	Range of exercise		Number			contractual			exercise		Number		exercise
	prices		of shares			life (in years)			price		of shares		price
			(number of shares in thousands)
	$0.00 - $10.00			1,100			8.5		$	2.55		689	$	2.84
	$10.01 - $20.00			124			3.41			15.82		124		15.82
	$20.01 - $30.00			83			5.19			23.58		79		23.66
	$30.01 - $41.25			16			0.84			33.68		16		33.68
				1,323			7.72		$	5.5		908	$	6.97
	Restricted Stock Awards
	On September 3, 2013, the Company issued 730,000 restricted stock awards.  The awards have a two-year vesting period and the fair value of the stock on the grant date was $0.266 per share.  The following table summarizes the status of the Company’s non-vested restricted stock as of September 30, 2013:
						Weighted
						Average
			Number			Grant Date			Aggregate
	(in thousands, except per share data)		of Units			Fair Value			Value
	Non-vested restricted stock at December 31, 2012			-		$	-
	Granted			730			0.27
	Exercised			-			-
	Cancelled			-			-
	Non-vested restricted stock at September 30, 2013			730		$	0.27		$	194
	Expected to vest at September 30, 2013			563		$	0.27		$	150
Restricted stock awards granted are scheduled to vest two years after the date of grant.  The cost of  each award is charged to operations over the vesting period.  On September 30, 2013, the weighted average remaining term of non-vested restricted stock was 1.9 years.
Forfeitures are estimated based on our historical forfeiture rates and standard probabilities of employee turnover based on the demographics of current option holders.
Unrecognized stock-based compensation related to restricted stock awards was approximately $188,000 as of September 30, 2013. This amount is expected to be expensed over a period of 1.9 years.

Net_Loss_per_Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	-4	Net Loss per Share
	Basic earnings per share is computed based upon the net loss available to common stock stockholders divided by the weighted average number of common stock shares outstanding during the period. The dilutive effect of common stock equivalents is included in the calculation of diluted earnings per share only when the effect of the inclusion would be dilutive. For the nine months ended September 30, 2013 and 2012, approximately 1.9 million and 1.6 million common stock equivalent shares associated with our stock option plans and unvested restricted shares, respectively, and approximately 1.3 million and 1.4 million common stock equivalent shares associated with our warrants, respectively, were excluded from the denominator in the diluted loss per share calculation, as their inclusion would have been antidilutive due to our net loss incurred during the periods presented.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	-5	Stockholders’ Equity
	The table below sets forth the outstanding warrants to purchase shares of common stock as of September 30, 2013:
	Offering Date		Outstanding Warrants		Exercise Price		Expiration Date		Status
	May-09			711,539	$	8.58		5/29/14	Exercisable
	Feb-10			420,000	$	27.5		2/1/15	Exercisable
				1,131,539
	On June 11, 2013, 220,383 warrants with an exercise price of $20.16 issued in June 2008 expired.  There were no warrants exercised during the nine months ended September 30, 2013.

Collaborative_Agreements

Collaborative Agreements	9 Months Ended
	Sep. 30, 2013
Collaborative Agreement [Abstract]	'
Collaborative Agreements	'
	-6	Collaborative Agreements
	In January 2010, we signed a research collaboration and license agreement (the Agreement) with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the Agreement, we licensed the world-wide rights to our preclinical hearing loss and balance disorders program. The Agreement was extended in January 2012 and again in January 2013.  Under the extensions, Novartis will fund research at GenVec through January 2014 to support the preclinical hearing loss and balance disorders program.  When the Agreement was executed in January 2010, we received a $5.0 million non-refundable upfront license fee and Novartis purchased $2.0 million of our common stock. The common stock was recorded at fair value of $3.3 million on the date of issuance. The non-refundable upfront license fee was recognized ratably over the original two-year research and collaboration term of the Agreement. Due to the pricing agreement associated with the sale of our common stock, revenue recognized from the non-refundable upfront license fee was $3.7 million by the end of the initial Agreement, as extended, in January 2014.  In addition, we will receive funding from Novartis for a research program focused on developing additional adenovectors for hearing loss. No revenue from the upfront license fee was recognized during the three months ended September 30, 2013 or 2012.   There was $47,000 and $152,000 of revenue recognized for research performed under the Agreement for the three months ended September 30, 2013 and 2012, respectively.  During the nine months ended September 30, 2013 and 2012 we recognized $0 and $78,000, respectively, of the upfront payment and $299,000 and $581,000, respectively, for research performed under the Agreement.
	Under the Agreement, we are eligible to receive milestones payments of up to $206.6 million, including up to $0.6 million for the achievement of preclinical development activities, up to $26.0 million for the achievement of clinical milestones (including non-rejection of an investigational new drug with respect to a covered product, the first patient visit in Phase I, Phase IIb, and Phase III clinical trials), up to $45.0 million for the receipt of regulatory approvals and up to $135.0 million for sales milestones. We have recognized $600,000 of milestone payments as a result of the successful completion of preclinical development activities prior to 2012.  There were no milestones achieved in 2012 or during the nine months ended September 30, 2013.
	In August 2010, we signed an agreement with Novartis for the supply of services relating to development materials in connection with the companies’ collaboration on the hearing loss and balance disorders program. Under this agreement, GenVec could receive approximately $13.0 million over four years to manufacture clinical trial material for up to two lead candidates. During the three months ended September 30, 2013 and 2012 we recognized $35,000 and $0.9 million, respectively, for services performed under this agreement.  During the nine months ended September 30, 2013 and 2012 we recognized $0.4 million and $3.0 million, respectively, for services performed under this agreement.
	In September 2012, we signed an agreement worth approximately $3.5 million with the U.S. Naval Medical Logistics Command to support dengue fever and malaria vaccine development efforts at the U.S. Naval Medical Research Center (NMRC).  Under the terms of the agreement, GenVec was responsible for producing clinical supplies of its malaria vaccine, which utilizes its novel, proprietary technology.  NMRC used the clinical material as part of its efforts to assess the safety and efficacy of these next-generation vectored vaccines using the clinical challenge model developed by NMRC and the Walter Reed Army Institute of Research (WRAIR) malaria vaccine programs, which now are unified as the U.S. Military Malaria Vaccine Program (USMMVP). Under the agreement, GenVec retained the right to commercialize this novel technology.  There was $1.4 million of revenue recognized under this contract during the three and nine-months ended September 30, 2013.  On July 29, 2013, the Company entered into a termination agreement with the U.S. Naval Medical Logistics Command to terminate the September 2012 agreement. That agreement was terminated pursuant to the Navy’s right of termination for convenience effective July 30, 2013 and was the result of a request by the Company, in light of the Company’s efforts to reduce its ongoing business operations.  The Company received approximately $1.4 million of the $3.5 million that the Company originally anticipated receiving over a three-year period pursuant to the September 2012 agreement.
	In April 2013, the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) announced that it would stop administering injections in its HVTN 505 clinical trial of an investigational HIV vaccine regimen because an independent data and safety monitoring board found during a scheduled interim review that the vaccine regimen did not prevent HIV infection nor reduce viral load (the amount of HIV in the blood) among vaccine recipients who later became infected with HIV. The HVTN 505 trial was designed to test the safety and efficacy of a two-part HIV vaccine regimen consisting of one vaccine designed to prime the immune system followed by another vaccine designed to boost the immune response. GenVec manufactured the adenovirus vector component utilized as the boost vaccine for this trial.

Litigation

Litigation	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block Supplement [Abstract]	'
Litigation	'
	-7	Litigation
	On February 3, 2012, a putative class action lawsuit captioned Satish Shah v. GenVec, Inc., et al. Civil Action. No. 8:12 CV-00341-DKC was commenced in the United States District Court for the District of Maryland against the Company, Paul H. Fischer, Douglas J. Swirsky, and Mark O. Thornton. Following appointment of a Lead Plaintiff group in April 2012, Lead Plaintiffs filed a pleading titled Amended Class Action Complaint for Violations of the Federal Securities Laws on July 6, 2012 (the Amended Complaint). In the Amended Complaint, Lead Plaintiffs asserted claims, purportedly on behalf of a class of persons who had purchased or acquired Company common stock between March 12, 2009 and March 30, 2010 (the Class Period), that the Company and the individual defendants had violated Section 10(b) of the Securities Exchange Act of 1934 (the Exchange Act), Rule 10b-5 promulgated thereunder, and Section 20(a) of the Exchange Act. Lead Plaintiffs alleged generally that defendants had made materially false or misleading statements or omissions concerning the prospects for the Company’s leading product candidate at the time, TNFerade, and the outcome of the then-ongoing clinical trial for TNFerade. Lead Plaintiffs alleged that these misrepresentations resulted in the Company’s common stock trading at artificially inflated prices throughout the Class Period. Lead Plaintiffs sought unspecified damages. On September 4, 2012, the Company and the individual defendants moved to dismiss the Amended Complaint in its entirety for failure to state a claim upon which relief can be granted.   On September 20, 2013, the Court granted this motion and dismissed the case in its entirety and with prejudice.  Lead Plaintiffs did not file an appeal.
	On March 12, 2012, a putative shareholder derivative action was commenced in the United States District Court for the District of Maryland against certain current and former members of our Board of Directors and the Company as a nominal defendant. The case is styled Garnitschnig v. Horovitz, et al. and generally arose out of the matters alleged to underlie the securities action. The plaintiff, who purported to bring the action derivatively on behalf of the Company, alleged that the defendants violated their fiduciary duties, wasted corporate assets, and were unjustly enriched by the receipt of compensation while serving as our directors. More particularly, the plaintiff’s Complaint alleged that as a result of the defendants’ failure of oversight, we disseminated misleading public statements and improperly continued with a clinical trial. While the Garnitschnig action did not seek a monetary recovery against the Company, plaintiff sought, among other things, an unspecified award of damages against the defendants, an order directing us to make certain changes to our corporate governance and oversight procedures, disgorgement by the defendants of compensation and an award of attorneys’ fees. Pursuant to the Court’s order dated April 5, 2013, the Garnitschnig case was stayed pending a decision on the motions to dismiss filed in the Shah action.  On October 2, 2013, the parties entered into a stipulation confirming that the stay of the Garnitschnig action was lifted and providing that, if the plaintiff elected to continue with the action, he would file an Amended Complaint on or before November 26, 2013.
	On November 1, 2013, the plaintiff in the Garnitschnig action filed an Amended Verified Shareholder Derivative and Class Action Complaint (the “Amended Complaint”) that supersedes the previous Complaint and now asserts claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets and alleged violations of the duty of candor.The plaintiff, who purports to bring the Amended Complaint both derivatively and as a shareholder class action, alleges that certain current and former members of the Board of Directors exceeded their authority under the Company’s 2011 Omnibus Incentive Plan (the “2011 Plan”) by exceeding certain limits applicable to both stock options and restricted stock. The Amended Complaint further alleges that Company’s Proxy Statement is materially false and misleading for failing to disclose the alleged violations of the 2011 Plan.The Complaint seeks both monetary relief and an injunction prohibiting the scheduled annual stockholders’ meeting of the Company until after corrective disclosures are provided to stockholders.The plaintiff in the Garnitschnig action also filed a motion for preliminary injunction at the same time that the Amended Complaint was filed. No hearing has been scheduled on this motion and Defendants have not yet filed any response.The Company intends to vigorously defend this action.
	We also are informed that defendants deny the material allegations of the Garnitschnig action and intend to continue vigorously defending the case.
	Given the inherent uncertainties of the litigation, the ultimate outcome of the Garnitschnig matter cannot be predicted at this time, nor can the amount of possible loss or range of loss, if any, be reasonably estimated.  The Company does not believe that, based on currently available information, the outcome of this proceeding will have a material adverse effect on our financial condition.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring	'
	-8	Restructuring
	On February 7, 2013, we eliminated nine positions as part of our efforts to lower operating costs to conserve capital.  The Company incurred $175,000 of expenses due to the position eliminations with approximately $85,000 paid in the first quarter of 2013 and $90,000 in the second quarter of 2013.
	On June 28, 2013, we announced the termination of 30 of our then-remaining 41 employees.   The Company incurred $304,000 of expenses in the second quarter due to the position eliminations, which resulted in cash expenditures of that amount in the third quarter.
	On September 3, 2013, we announced that Cynthia Collins, our then President and Chief Executive Officer, had departed the Company and resigned as a member of its Board of Directors.  Douglas J. Swirsky, who had served as GenVec’s Senior Vice President and Chief Financial Officer since 2006, has been named as the Company’s President and Chief Executive Officer and has been appointed to the Company’s Board of Directors.  The Company incurred $1.0 million of expense in the third quarter due to the departure of Ms. Collins that will be paid out over 18 months, in accordance with her employment agreement.
	Additionally we have evaluated certain of our long-lived assets and determined that approximately $229,000 of these assets have been impaired during the second quarter of 2013.
	Costs associated with the elimination of positions have been recorded as a general and administrative personnel cost.  Costs associated with the impairment of long-lived assets have been recorded as a general and administrative loss on long-lived assets.

General_Policies

General (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The condensed financial statements included herein have been prepared by GenVec, Inc. (GenVec, we, our, or the Company) without audit pursuant to the rules and regulations of the Securities and Exchange Commission (SEC).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. We believe the disclosures are adequate to make the information presented not misleading.  The condensed financial statements included herein should be read in conjunction with the financial statements and the notes thereto included in our 2012 Annual Report on Form 10-K filed with the SEC.
	In the opinion of management, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of September 30, 2013 and December 31, 2012, the results of its operations for the three-month and nine-month periods ended September 30, 2013 and September 30, 2012, and cash flows for the nine-month periods ended September 30, 2013 and September 30, 2012.  The results of operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Business	'
	Business
	GenVec is a biopharmaceutical company working with leading companies and organizations such as Novartis Institutes for BioMedical Research, Inc. (together with Novartis AG and its subsidiary corporations, including Novartis Pharma AG, Novartis) and the U.S. Government to leverage GenVec’s proprietary gene-delivery technologies to address the prevention and treatment of significant health concerns. GenVec’s lead program, in the field of regenerative medicine and licensed to Novartis, is for the development of novel treatments for hearing loss and balance disorders.  We anticipate that Novartis will initiate a phase 1 clinical trial in 2014.
	Key components of our strategy moving forward include:
		·	Working with Novartis to facilitate the development of first-in-class products for the treatment of hearing and balance disorders;
		·	Developing a sustainable revenue base by licensing rights to our proprietary vector and cell line technologies to additional companies and organizations;
		·	Licensing our pre-clinical vaccine candidates for the prevention of RSV and the treatment of HSV-2 infection; and
		·	Minimizing our cash burn by operating our business in a cost-efficient manner.
	Our core technology has the important advantage of localizing protein delivery in the body. This is accomplished by using our adenovector platform to locally deliver genes to cells, which then direct production of the desired protein. This approach reduces side effects typically associated with systemic delivery of proteins. For vaccines, the goal is to induce an immune response against a target protein or antigen. This is accomplished by using an adenovector to deliver a gene that causes production of an antigen, which then stimulates the desired immune reaction by the body.
	Our research and development activities have been focused on identifying product candidates that utilize our technology platform and represent potential commercial opportunities. For example, preclinical research in hearing loss and balance disorders has indicated that the delivery of the atonal gene using GenVec’s adenovector technology may have the potential to restore hearing and balance function. We are working with Novartis on the discovery and development of novel treatments for hearing loss and balance disorders. There are currently no effective therapeutic treatments available for patients who have lost all balance function, and hearing loss remains a major unmet medical problem.
Recent Events	'
	Recent Events
	Our current operating strategy was adopted on September 4, 2013, when we announced that our Board of Directors withdrew a Plan of Complete Liquidation and Dissolution of the Company (the Plan of Dissolution) that had been adopted by the Board of Directors on May 24, 2013, subject to stockholder approval. After announcing the approval of the Plan of Dissolution by the Board of Directors, the Company received several proposals for transactions with the Company, including transactions to purchase all or portions of the Company's assets or to engage in mergers with private companies that were looking to use the Company principally as a means to become publicly traded. As part of the Board of Directors' efforts to seek to maximize the value for stockholders and to provide stockholders with appropriate information for their consideration, the Board of Directors considered these proposals. Given that it was considering these proposals, the Board of Directors also authorized Cannacord Genuity Inc., an investment banking firm, to solicit additional proposals for the acquisition of our assets, and on June 24, 2013, the Company announced publicly that it had received and was considering proposals. The Board of Directors viewed the ability of the counterparties to complete the proposed transactions, in a timely manner, if at all, as extremely risky, the prospects for preserving value as very uncertain and the likelihood of receiving significant consideration in an asset sale as unlikely. The process that the Company went through in evaluating alternative proposals, the business developments during that time, the challenges in monetizing the Company's assets in the near term for values the Board of Directors thought would be fair, and the time that the process took, led the Board of Directors to conclude on September 4, 2013 that it was in the best interests of the Company's stockholders to withdraw the Plan of Dissolution and pursue the Company's current operating strategy.
	In going through the process of considering the Plan of Dissolution and alternative transactions, we worked to terminate or further curtail a number of our contractual obligations and a significant portion of our operations. We also ceased to support some programs at the levels at which they were previously supported, or at all. On July 29, 2013, for example, we entered into a modification with the U.S. Naval Medical Logistics Command to terminate contractual obligations under our agreement related to dengue fever and malaria vaccine development efforts at the U.S. Naval Medical Research Center. In furtherance of these efforts, we announced on June 28, 2013, that we had terminated the employment of 30 of our then remaining 41 employees, and as of the date of this Quarterly Report on Form 10-Q we have 9 employees.
	Our estimated future capital requirements are uncertain and could change materially as a result of many factors, including the success of our collaboration with Novartis and our success in entering into other licensing or collaboration transactions. Based on our current business operations, we estimate we have sufficient resources to fund our operations through at least the end of 2014.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements, in conformity with U.S. generally accepted accounting principles, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities on the date of the financial statements, and revenues and expenses during the period. Critical accounting estimates involved in applying our accounting policies are those that require management to make assumptions about matters that are highly uncertain at the time the accounting estimate was made and those for which different estimates reasonably could have been used for the current period. Critical accounting estimates are also those which are reasonably likely to change from period to period and would have a material impact on the presentation of our financial condition, results of operations, or cash flows. Our most critical accounting estimates relate to accounting policies for strategic alliance and research contract revenues, clinical trial expenses and research and development activities, and stock-based arrangements. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results could differ from these estimates.
Revenue Recognition	'
	Revenue Recognition
	Revenue is recognized when all four of the following criteria are met (i) a contract is executed, (ii) the contract price is fixed and determinable, (iii) delivery of the services or products has occurred, and (iv) collectability of the contract amounts is considered probable.
	Our collaborative research and development agreements provide for upfront license fees, research payments, and/or substantive milestone payments.  Upfront non-refundable fees associated with license and development agreements where we have continuing involvement in the agreement are recorded as deferred revenue and recognized over the estimated service period.  If the estimated service period is subsequently modified, the period over which the upfront fee is recognized is modified accordingly on a prospective basis.  Non-refundable research and development fees for which no future performance obligations exist are recognized when collection is assured.  Substantive milestone payments are considered performance payments and are recognized upon achievement of the milestone if all of the following criteria are met: (i) achievement of the milestone involves a degree of risk and was not reasonably assured at the inception of the arrangement; (ii) substantive effort is involved in achieving the milestone; and (iii) the amount of the milestone payment is reasonable in relation to all of the deliverables and payment terms within the arrangement.  Determination of whether a milestone meets the aforementioned conditions involves the judgment of management.
	Research and development revenue from cost-reimbursement and cost-plus fixed-fee agreements is recognized as earned based on the performance requirements of the contract.  Revisions in revenues, cost, and billing factors, such as indirect rate estimates, are accounted for in the period of change.  Reimbursable costs under such contracts are subject to audit and retroactive adjustment.  Contract revenues and accounts receivable reported in the financial statements are recorded at the amount expected to be received.  Contract revenues are adjusted to actual upon final audit and retroactive adjustment.  Estimated contractual allowances are provided based on management’s evaluation of current contract terms and past experience with disallowed costs and reimbursement levels.  Payments received in advance of work performed are recorded as deferred revenue.
	Research and development revenue from fixed-price best efforts arrangements is recognized as earned based on the performance requirements of the contract.  Revenue under these arrangements is recognized when delivery to and acceptance by the customer has been received.  During the period of performance, recoverable contract costs are accumulated on the balance sheet in other current assets, but no revenue or profit is recorded prior to customer acceptance of the contractually stated deliverables.  Recoverable contract costs that are accumulated on the balance sheet include all direct costs associated with the arrangement and an allocation of indirect costs.  Payments received in advance of customer acceptance are recorded as deferred revenue.  Once customer acceptance has been received, revenue and recoverable contract costs are recognized.  Over the course of the arrangement, we routinely evaluate whether revenue and profitability should be recognized in the current period.  Any known or probable losses on projects are charged to operations in the period in which such losses are determined.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (Topic 220). The standard requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. The Company’s adoption of the provisions of this guidance on January 1, 2013 did not have a material impact on our financial position, results of operations, or cash flows.
	There were no other new pronouncements effective as of September 30, 2013 that had a material effect on our financial position, results of operations, or cash flows.  Additionally, other new pronouncements issued but not effective until after September 30, 2013 are not expected to have a material effect on our financial position, results of operations, or cash flows.
Reclassifications	'
	Reclassifications
	Certain reclassifications have been made to prior period amounts to conform to our current period presentation.  Such reclassifications have no effect on net loss as previously reported.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Recorded at Fair Value on Recurring Basis on Condensed Balance Sheet	'
	The following table presents information about assets and liabilities recorded at fair value on a recurring basis on the Condensed Balance Sheet as of September 30, 2013:
				Quoted Prices in
				Active Markets for		Significant
		Total Carrying		Identical		Other Observable
		Value on the		Assets/Liabilities		Inputs
	(In thousands)	Balance Sheet		(Level 1)		(Level 2)
	Assets:
	Cash and cash equivalents	$	4,970	$	4,970	$	-
	Corporate notes and bonds		654		-		654
	U.S. Government and agency securities		1,419		-		1,419
	Equity security		58		58		-
	Total assets at fair value	$	7,101	$	5,028	$	2,073
	The following table presents information about assets and liabilities recorded at fair value on a recurring basis as of December 31, 2012 on the Condensed Balance Sheet:
				Quoted Prices in
				Active Markets for		Significant
		Total Carrying		Identical		Other Observable
		Value on the		Assets/Liabilities		Inputs
	(In thousands)	Balance Sheet		(Level 1)		(Level 2)
	Assets:
	Cash and cash equivalents	$	4,150	$	4,150	$	-
	Corporate notes and bonds		6,871		-		6,871
	U.S. Government and agency securities		4,189		-		4,189
	Equity security		45		45		-
	Total assets at fair value	$	15,255	$	4,195	$	11,060

StockBased_Compensation_Expens1

Stock-Based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Stock-Based Compensation Expense Related to Employee Stock Options	'
	The following table summarizes stock-based compensation expense related to employee stock options for the three-month and nine-month periods ended September 30, 2013 and September 30, 2012, which was allocated as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013		2012
		(in thousands)						(in thousands)
	Research and development	$	83		$	208		$	503	$	636
	General and administrative		200			104			406		314
		$	283		$	312		$	909	$	950
Weighted-Average Assumptions Used in Valuation of Stock Option	'
	We use the Black-Scholes pricing model to value stock options.  The estimated fair value of employee stock options granted during the nine months ended September 30, 2013 and 2012 was calculated using the Black-Scholes model with the following weighted-average assumptions:
		For the Nine				For the Nine
		Months Ended				Months Ended
		September 30, 2013				September 30, 2012
	Risk-free interest rate		1.05	%			1.04	%
	Expected dividend yield		0	%			0	%
	Expected volatility		98.09	%			97.97	%
	Expected life (years)		6.2				6.34
	Weighted-average fair value of options granted	$	1.22			$	2
Stock Option Activity	'
	The following table summarizes the stock option activity for the nine months ended September 30, 2013:
					Weighted			Weighted
					average			average		Aggregate
		Number			exercise			contractual		intrinsic
	(in thousands,	of shares			price			life (years)		value
	except exercise price and contractual term data)
	Stock options outstanding, December 31, 2012		1,409		$	7.06
	Granted		646			1.57
	Forfeited		-549			2.29
	Expired		-183			13.27
	Stock options outstanding at September 30, 2013		1,323		$	5.5			7.72	$	9
	Vested or expected to vest at September 30, 2013		1,258		$	5.68			7.65	$	9
	Exercisable at September 30, 2013		908		$	6.97			7.19	$	-
Summary of Stock Options Outstanding	'
	The following table summarizes information about our stock options outstanding as of September 30, 2013:
		Outstanding								Exercisable
					Weighted
					average			Weighted				Weighted
					remaining			average				average
	Range of exercise	Number			contractual			exercise		Number		exercise
	prices	of shares			life (in years)			price		of shares		price
		(number of shares in thousands)
	$0.00 - $10.00		1,100			8.5		$	2.55		689	$	2.84
	$10.01 - $20.00		124			3.41			15.82		124		15.82
	$20.01 - $30.00		83			5.19			23.58		79		23.66
	$30.01 - $41.25		16			0.84			33.68		16		33.68
			1,323			7.72		$	5.5		908	$	6.97
Nonvested Restricted Stock Units Activity	'
	On September 3, 2013, the Company issued 730,000 restricted stock awards.  The awards have a two-year vesting period and the fair value of the stock on the grant date was $0.266 per share.  The following table summarizes the status of the Company’s non-vested restricted stock as of September 30, 2013:
					Weighted
					Average
		Number			Grant Date			Aggregate
	(in thousands, except per share data)	of Units			Fair Value			Value
	Non-vested restricted stock at December 31, 2012		-		$	-
	Granted		730			0.27
	Exercised		-			-
	Cancelled		-			-
	Non-vested restricted stock at September 30, 2013		730		$	0.27		$	194
	Expected to vest at September 30, 2013		563		$	0.27		$	150

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Summary of Warrants Outstanding	'
	The table below sets forth the outstanding warrants to purchase shares of common stock as of September 30, 2013:
	Offering Date	Outstanding Warrants		Exercise Price		Expiration Date		Status
	May-09		711,539	$	8.58		5/29/14	Exercisable
	Feb-10		420,000	$	27.5		2/1/15	Exercisable
			1,131,539

Assets_and_Liabilities_Recorde

Assets and Liabilities Recorded at Fair Value on Recurring Basis on Condensed Balance Sheet (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Assets:	'	'	'	'
Cash and cash equivalents	$4,970	$4,150	$4,972	$4,114
Fair Value, Measurements, Recurring	'	'	'	'
Assets:	'	'	'	'
Cash and cash equivalents	4,970	4,150	'	'
Corporate notes and bonds	654	6,871	'	'
U.S. Government and agency securities	1,419	4,189	'	'
Total assets at fair value	7,101	15,255	'	'
Fair Value, Measurements, Recurring | Equity Security	'	'	'	'
Assets:	'	'	'	'
Total assets at fair value	58	45	'	'
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)	'	'	'	'
Assets:	'	'	'	'
Cash and cash equivalents	4,970	4,150	'	'
Corporate notes and bonds	0	0	'	'
U.S. Government and agency securities	0	0	'	'
Total assets at fair value	5,028	4,195	'	'
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) | Equity Security	'	'	'	'
Assets:	'	'	'	'
Total assets at fair value	58	45	'	'
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)	'	'	'	'
Assets:	'	'	'	'
Cash and cash equivalents	0	0	'	'
Corporate notes and bonds	654	6,871	'	'
U.S. Government and agency securities	1,419	4,189	'	'
Total assets at fair value	2,073	11,060	'	'
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Equity Security	'	'	'	'
Assets:	'	'	'	'
Total assets at fair value	$0	$0	'	'

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Fair Value, Measurement Inputs, Disclosure [Line Items]	'	'
Net unrealized gain (loss) included in comprehensive income related to marketable securities	$13,000	$1,000

StockBased_Compensation_Expens2

Stock-Based Compensation Expense - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stockholders Equity [Line Items]	'	'	'	'
Expected life (years)	'	'	'6 years 2 months 12 days	'6 years 4 months 2 days
Unrecognized stock-based compensation expense	'	'	$700,000	'
Vested or expected to vest	'	'	'7 years 7 months 24 days	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	$1.22	$2
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2	'	'	'7 years 8 months 19 days	'
Share Based Compensation	283,000	312,000	909,000	950,000
US Treasury Securities	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum	'	'	1.00%	0.81%
Share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum	'	'	2.63%	1.58%
Restricted Stock	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	730	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'2 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	$0.27	'
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2	'	'	'1 year 10 months 24 days	'
Share Based Compensation	'	'	$188,000	'
Stock Option	'	'	'	'
Stockholders Equity [Line Items]	'	'	'	'
Vested or expected to vest	'	'	'2 years 4 months 6 days	'

Summary_of_Stock_Based_Compens

Summary of Stock Based Compensation Expense Related to Employee Stock Options (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash charges for stock-based compensation	$283	$312	$909	$950
Research and development	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash charges for stock-based compensation	83	208	503	636
General and administrative	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Non-cash charges for stock-based compensation	$200	$104	$406	$314

Black_Scholes_Model_Weighted_A

Black Scholes Model Weighted Average Assumptions Used to Calculate Weighted Average Estimated Fair Value of Employee Stock Options Granted (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk-free interest rate	1.05%	1.04%
Expected dividend yield	0.00%	0.00%
Expected volatility	98.09%	97.97%
Expected life (years)	'6 years 2 months 12 days	'6 years 4 months 2 days
Weighted-average fair value of options granted	$1.22	$2

Stock_Option_Activity_Detail

Stock Option Activity (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Number of shares	'
Stock options outstanding	1,409
Granted	646
Forfeited	-549
Expired	-183
Stock options outstanding	1,323
Vested or expected to vest	1,258
Exercisable	908
Weighted average exercise price	'
Stock options outstanding	$7.06
Granted	$1.57
Cancelled	$2.29
Expired	$13.27
Stock options outstanding	$5.50
Vested or expected to vest	$5.68
Exercisable	$6.97
Weighted average contractual life (years)	'
Stock options outstanding	'7 years 8 months 19 days
Vested or expected to vest	'7 years 7 months 24 days
Exercisable	'7 years 2 months 8 days
Aggregate intrinsic value	'
Stock options outstanding	$9
Vested or expected to vest	9
Exercisable	$0

Summary_of_Stock_Options_Outst

Summary of Stock Options Outstanding (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Outstanding Number of shares	1,323
Outstanding Weighted average remaining contractual life (in years)	'7 years 8 months 19 days
Outstanding Weighted average exercise price	$5.50
Exercisable Number of shares	908
Exercisable Weighted average exercise price	$6.97
Range 1	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$0
Range of exercise prices, maximum	$10
Outstanding Number of shares	1,100
Outstanding Weighted average remaining contractual life (in years)	'8 years 6 months
Outstanding Weighted average exercise price	$2.55
Exercisable Number of shares	689
Exercisable Weighted average exercise price	$2.84
Range 2	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$10.01
Range of exercise prices, maximum	$20
Outstanding Number of shares	124
Outstanding Weighted average remaining contractual life (in years)	'3 years 4 months 28 days
Outstanding Weighted average exercise price	$15.82
Exercisable Number of shares	124
Exercisable Weighted average exercise price	$15.82
Range 3	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$20.01
Range of exercise prices, maximum	$30
Outstanding Number of shares	83
Outstanding Weighted average remaining contractual life (in years)	'5 years 2 months 8 days
Outstanding Weighted average exercise price	$23.58
Exercisable Number of shares	79
Exercisable Weighted average exercise price	$23.66
Range 4	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of exercise prices, minimum	$30.01
Range of exercise prices, maximum	$41.25
Outstanding Number of shares	16
Outstanding Weighted average remaining contractual life (in years)	'10 months 2 days
Outstanding Weighted average exercise price	$33.68
Exercisable Number of shares	16
Exercisable Weighted average exercise price	$33.68

Summary_of_NonVested_Restricte

Summary of Non-Vested Restricted Stock (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Summary Of Non-Vested Restricted Stock [Line Items]	'	'
Weighted Average Grand Date Fair Value, Granted	$1.22	$2
Restricted Stock	'	'
Summary Of Non-Vested Restricted Stock [Line Items]	'	'
Number of Units, Beginning Balance	0	'
Number of Units, Granted	730	'
Number of Units, Exercised	0	'
Number of Units, Cancelled	0	'
Number of Units, Ending Balance	730	'
Number of Units, Expected to vest at September 30, 2013	563	'
Weighted Average Grand Date Fair Value, Beginning Balance	$0	'
Weighted Average Grand Date Fair Value, Granted	$0.27	'
Weighted Average Grand Date Fair Value, Exercised	$0	'
Weighted Average Grand Date Fair Value, Cancelled	$0	'
Weighted Average Grand Date Fair Value, Ending Balance	$0.27	'
Weighted Average Grand Date Fair Value, Expected to vest at September 30, 2013	$0.27	'
Aggregate Value, Ending Balance	$194	'
Aggregate Value, Expected to vest at September 30, 2013	$150	'

Net_Loss_per_Share_Additional_

Net Loss per Share - Additional Information (Detail)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Warrant	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common stock equivalent shares excluded from the denominator in the diluted loss per share calculation	1.3	1.4
Stock Option and Restricted Stocks	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Common stock equivalent shares excluded from the denominator in the diluted loss per share calculation	1.9	1.6

Outstanding_Warrants_to_Purcha

Outstanding Warrants to Purchase Shares of Common Stock (Detail)	Sep. 30, 2013	Jun. 11, 2013	Sep. 30, 2013	Sep. 30, 2013
			Warrant 1	Warrant 2
Class of Warrant or Right [Line Items]	'	'	'	'
Offering Date	'	'	'2009-05	'2010-02
Outstanding Warrants	1,131,539	'	711,539	420,000
Exercise Price	'	20.16	8.58	27.5
Expiration Date	'	'	'5/29/2014	'2/1/2015
Status	'	'	'Exercisable	'Exercisable

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail)	Jun. 11, 2013
Class Of Warrant Or Right [Line Items]	'
Warrant issued	220,383
Warrant Exercise Price	20.16

Collaborative_Agreements_Addit

Collaborative Agreements - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2012

Jan. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2010

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 31, 2010

Contract Termination

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Collaboration and License Agreement

Service Agreements

Service Agreements

Service Agreements

Service Agreements

Service Agreements

Service Agreements

Service Agreements

Preclinical Development Activities

Preclinical Development Activities

Clinical Milestone Events

Regulatory Approvals

Sales Milestones

Maximum

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non refundable upfront license fee

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative arrangement shares issued value

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative arrangement shares issued fair value

'

3,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative arrangement agreement research and collaboration term

'3 years

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue, additions

'

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue, revenue recognized

'

'

'

'

0

78,000

'

'

'

'

'

'

'

'

'

'

'

'

Research revenue

'

'

'

'

299,000

581,000

'

'

'

'

'

'

'

'

'

'

'

'

Collaborative arrangement expected service revenue

'

'

206,600,000

'

206,600,000

'

'

600,000

26,000,000

45,000,000

135,000,000

'

'

'

'

'

'

'

Milestone method, revenue recognized

'

'

'

'

'

'

600,000

'

'

'

'

'

'

'

'

'

'

'

Service revenue

'

'

'

'

'

'

'

'

'

'

'

1,400,000

13,000,000

35,000

900,000

400,000

3,000,000

'

Collaborative arrangement agreement service term

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

Number of candidates

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

Revenues from other services

'

'

'

'

'

'

'

'

'

'

'

3,500,000

'

'

'

1,400,000

'

'

Revenue From Research Work

'

'

$47,000

$152,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring_Additional_Infor

Restructuring - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Sep. 30, 2012
Restructuring [Line Items]	'	'	'	'	'
Restructuring costs	$1,000,000	$304,000	$175,000	'	'
Payment of costs incurred	'	90,000	85,000	'	'
Impairment of long lived assets	'	$229,000	'	$229,000	$0